Clinical Research Directory
Browse clinical research sites, groups, and studies.
UGX202 Injection in Patients With Advanced Retinitis Pigmentosa
Sponsor: Suzhou UgeneX Therapeutics Co., Ltd.
Summary
The primary objective of this clinical trial is to evaluate the safety and tolerability of a single intravitreal injection of the gene therapy drug UGX202 in patients with advanced RP. The secondary objective is, to assess the preliminary efficacy of a single intravitreal injection of the gene therapy drug UGX202 in treating patients with advanced RP.
Official title: Study to Evaluate the Safety and Preliminary Efficacy of UGX202 Injection in Patients With Advanced Retinitis Pigmentosa
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
6
Start Date
2026-01
Completion Date
2027-03
Last Updated
2025-12-31
Healthy Volunteers
No
Conditions
Interventions
UGX202 injection
Comparison of different dosages of UGX202
Locations (1)
Eye & ENT Hospital of Fudan University
Shanghai, Shanghai Municipality, China